Pharmaceutical Consulting

Navigating pharmaceutical markets across China and the Asia-Pacific region requires more than ambition. With complex regulatory frameworks, evolving pricing systems, and competitive dynamics, companies need more than just local presence, they need a partner with deep industry knowledge, robust strategy, and executional strength.

Cisema offers pharmaceutical consulting services that help companies in the pharmaceutical industry, including biotech, gene therapy, and life sciences innovators, prepare for market entry, accelerate approvals, and optimize commercialization across the region. We support clients with a comprehensive understanding of regulatory pathways, drug development stages, and clinical research demands.

Chinese testing
Pharmaceutical Market Access Consulting
Pharma and Biotech Innovation

Our services include:

Regulatory strategy and planning to reduce risks and eliminate uncertainty
Accelerated registration pathways to shorten time-to-market streamline the drug development process
End-to-end compliance support to meet regional requirements and safeguard operations
Market access strategies tailored to to maximize value, patient reach, and commercial success.

Whether you’re initiating clinical trials, navigating drug registration, or expanding across Asia Pacific, we deliver targeted solutions and proven results across all stages of development.

Work with Cisema to stay ahead of regulatory trends, reduce time-to-market, and achieve sustainable success across China and the broader Asia-Pacific region.

Discover Our Pharmaceutical Consulting Services

Pharmaceutical Development & Strategy

Drive successful market entry and growth with confidence. Our pharmaceutical regulatory consulting experts support biotech and life sciences companies in streamlining drug development, accelerating approvals, and achieving commercialization through tailored strategies, clinical insights, and end-to-end compliance solutions.

Scientific, Technical & Clinical Due Diligence
Development Strategy & Gap Analysis
Regulatory and Clinical Strategy Development
Health Authority Interaction
Scientific, Medical, Technical & Regulatory Writing

Health Economics & Market Access

Accelerate access across China and Asia Pacific with confidence. Our market access consultants help life sciences companies optimize patient access, navigate pricing and reimbursement challenges, and enable commercial success through real world evidence, health economics, and tailored access strategies.

Market Intelligence
Pricing and Reimbursement (P&R) Landscape Analysis
Strategic Market Entry & Pricing Models
Reimbursement Strategy
Competitive Dynamics Assessment
Stakeholder Engagement & Market Insights

Pharmaceutical Regulatory Affairs

Navigate regulatory complexity across China and Asia Pacific with confidence. Our regulatory affairs consulting experts support life sciences clients with strategic planning, compliant submissions, and local representation to accelerate approvals and ensure market readiness.

Scientific, Technical and Regulatory Strategy
Procedure Management
CMC & Compliance
Health Authority Interaction
Labeling Management & Promotional Material Review
Legal Agent / Domestic Responsible Agent

Pharmaceutical Quality Management & Compliance

Ensure regulatory excellence across China and Asia Pacific with confidence. Our quality management and compliance experts help life sciences organizations strengthen GxP systems, streamline audits, and maintain inspection readiness to safeguard market access and operational performance.

Review, Assessment & Pre-audits of GxP/QMS/SOPs
Ingredient Compliance Analysis
Vendor Audit and Management
Pre-approval Inspection
China & overseas factory audits
Official NMPA Inspection Assistance

Pharmacovigilance

Ensure drug safety and regulatory compliance across China and Asia Pacific with confidence. Our pharmacovigilance consulting experts support life sciences companies in managing risks, meeting evolving safety requirements, and maintaining market authorization through end-to-end PV solutions tailored to local regulations.

Signal Management
Risk Management
Case Safety Report Management
Clinical Trial Safety
Pharmacovigilance System Audit & CAPA
Post-Marketing Surveillance

Why Cisema?

Cisema brings together regional expertise, industry insights, and operational excellence to support pharmaceutical success. We work closely with our clients to address regulatory, strategic, and quality challenges, ensuring timely approvals, sustainable market access, and efficient commercialization. Our consultants are trusted by leaders across the life sciences industry for their depth of experience and commitment to quality outcomes.


We help you:

Prepare your product pipeline for China and the Asia Pacific region
Develop effective strategies aligned with local healthcare policy
Respond quickly to evolving trends and regulatory shifts
Navigate compliance requirements with confidence
Optimize clinical trial processes, data use, and real-world evidence

Whether your focus is innovation, access, or long-term growth, our consulting solutions are built to deliver measurable results.

Pharma and healthcare expertise from the Cisema team

Request a Proposal from Our Pharma Team

Let Cisema help turn your plans into reality.

Angebot anfordern

Useful Articles

View More

A Complete Guide to China Hyaluronic Acid Registration

A complete guide to China hyaluronic acid registration, covering classification, NMPA requirements, and compliance steps for manufacturers.

August 3, 2026
A Complete Guide to China Hyaluronic Acid Registration

China NMPA Fee Catalogue for Drugs & Medical Devices

Learn the latest China NMPA registration fees for imported and domestic drugs and medical devices.

August 3, 2026
China NMPA Fee Catalogue for Drugs & Medical Devices

A Guide to Malaysia Drug–Medical Device Combination Products: Classification & Regulatory Pathways

Learn how Malaysia classifies drug–medical device combination products and how the PMOA determines pathways and compliance responsibilities.

August 3, 2026
A Guide to Malaysia Drug–Medical Device Combination Products: Classification & Regulatory Pathways
Laboratory professional in protective eyewear, hair cover, sterile gown, and blue nitrile gloves examining a filled syringe in a clean laboratory environment.

How Singapore Accelerates ASEAN Market Entry for Medical Devices, Pharma, & Cosmetics

This guide explains Singapore’s HSA regulatory system and why it is a strategic first step for entering Southeast Asian markets with medical devices, pharmaceuticals, and cosmetics.

August 3, 2026
How Singapore Accelerates ASEAN Market Entry for Medical Devices, Pharma, & Cosmetics

China’s 15th Five-Year Plan: Implications for Drugs, Medical Devices, & Market Access 

China’s 15th Five-Year Plan signals stronger support for innovative drugs, advanced medical devices, reimbursement reform, and NMPA regulatory pathways.

August 3, 2026
China’s 15th Five-Year Plan: Implications for Drugs, Medical Devices, & Market Access 
Chinese flag against a blue sky

Cisema Expands into South Korea

Supporting foreign manufacturers entering South Korea with regulatory services for medical devices, IVDs, and quasi-drugs.

August 3, 2026
Cisema Expands into South Korea
Seoul skyline in the early evening
Previous
Previous

Other Industries We Support

In addition to pharmaceuticals and biotech, we offer consulting services across regulated industries, including medical devices, IVDs, cosmetics, health foods, veterinary products, and other industrial and consumer goods. Our team ensures tailored regulatory compliance strategies, regardless of product category or manufacturing model.

Medical Devices

In-Vitro Diagnostics

Biotech

Cosmetics

Health Foods & Supplements

Veterinary Medicines & Products

Industrial Goods & Consumer Products

Aktuelle Einblicke

Mehr anzeigen

CDE Releases 2025 Annual Report on the Progress of Clinical Trials for New Drug Registration in China

Explore the latest data on China’s clinical research landscape, including record trial activity, shorter development timelines, and emerging R&D trends.

August 3, 2026
CDE Releases 2025 Annual Report on the Progress of Clinical Trials for New Drug Registration in China

China Targets 65 Drugs in Its 12th National Procurement Round

The 12th national VBP round introduces tighter quality, manufacturing, and IP requirements that pharmaceutical companies must meet to compete.

August 3, 2026
China Targets 65 Drugs in Its 12th National Procurement Round

China CDE Defines Classification Rules for Cell & Gene Therapy Drugs

New NMPA CDE guidelines define CTMP and GTMP boundaries, affecting development strategy, CMC planning, and regulatory engagement in China.

August 3, 2026
China CDE Defines Classification Rules for Cell & Gene Therapy Drugs

China's 2026 Essential Medicines Adds More Innovative Drugs

China's updated National Essential Medicines List expands access to innovative medicines, creating new opportunities and strategic considerations for pharmaceutical companies.

August 3, 2026
China's 2026 Essential Medicines Adds More Innovative Drugs
A middle-aged man with glasses is looking down thoughtfully as he pours medication or pills from a small white bottle with a yellow label into his open palm.

China NMPA Expands Priority Review for Chemical API Marketing Authorization Applications

China's NMPA expands priority review eligibility for chemical API marketing authorization applications, supporting domestic API production and drug supply.

August 3, 2026
China NMPA Expands Priority Review for Chemical API Marketing Authorization Applications
Chemical API Manufacturing

China Releases 2026 Anti-Corruption Priorities for Pharmaceutical Sales & Medical Services

China's 2026 enforcement priorities expand scrutiny of pharmaceutical sales, procurement, pricing, data security, and compliance across the healthcare sector.

August 3, 2026
China Releases 2026 Anti-Corruption Priorities for Pharmaceutical Sales & Medical Services
Zurück
Zurück

Get in Touch with Our Pharmaceutical Consultants

Speak to our consultants to learn how our comprehensive services, regulatory guidance, and operational expertise can help you stay ahead in the complex pharmaceutical regulatory environment of China and the Asia Pacific region.

Angebot anfordern